Mirae Asset Global Investments Co., Ltd. Aerie Pharmaceuticals Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$6.37 - $15.23 $12,517 - $29,926	1,965 Added 5.94%	35,026 $530,000
Q2 2022 Jul 26, 2022	BUY	$4.95 - $9.16 $163,651 - $302,838	33,061 New	33,061 $248,000
Q1 2022 May 10, 2022	SELL	$5.64 - $9.8 $60,195 - $104,595	-10,673 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$7.02 - $13.33 $1,691 - $3,212	241 Added 2.31%	10,673 $75,000
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $118,090 - $173,484	10,432 New	10,432 $119,000
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $1.3 Million - $1.91 Million	-27,108 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$51.15 - $61.0 $626,536 - $747,189	-12,249 Reduced 31.12%	27,108 $1.47 Million
Q4 2017 Feb 12, 2018	BUY	$50.85 - $65.1 $1.39 Million - $1.77 Million	27,257 Added 225.26%	39,357 $2.35 Million
Q3 2017 Nov 08, 2017	SELL	$48.6 - $60.1 $7,630 - $9,435	-157 Reduced 1.28%	12,100 $588,000
Q2 2017 Aug 14, 2017	BUY	N/A	12,257	12,257 $644,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.